ClinicalTrials.gg
CompletedNCT03326583Updated May 9, 2023Results posted

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

A Phase 2 interventional study of Patiromer in ESRD, Hyperkalemia and End Stage Renal Disease, sponsored by Dominic Raj. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Dominic Raj · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
408th of 638
27 · median 48
Started
2017
with 36 others
Phase 2
87 of 765
4 open now
Registered
491st of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 408th largest by enrollment of the 638 interventional ones that give a count, is one of 37 that started in 2017, is one of 87 in phase 2, and was the 491st registered.

Kidney Failure, Chronic

2,114 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia (potassium greater than 5 milliequivalents per liter) is a non-randomized, crossover study. This is an open-label, pilot clinical trial with 3 sequential phases of (a) 2 weeks of no intervention, (b) 12 weeks of Patiromer treatment, and (c) 6 weeks of no intervention. Treatment with Patiromer will be initiated at a dose of 8.4 grams, once daily and observed for a week, then uptitrated to 16.8 grams once daily. Eligible study subjects will collect stool samples and provide blood and urine samples.

03

Conditions studied

  • ESRD
  • Hyperkalemia
  • End Stage Renal Disease

Keywords

  • End Stage Renal Disease
  • ESRD
  • Hyperkalemia
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects on stable hemodialysis for more than 90 days.
  • Age 18-85 years.
  • Persistent hyperkalemia, defined as elevated serum potassium > 5.0 mEq/L in more than 2 occasions during the previous 3 months.

Exclusion criteria

Exclusion Criteria:

  • Use of pre- or probiotics during the past 2 months
  • Use of antibiotics within the past 2 months, if the patient received a single course of antibiotic.
  • Presence of chronic wound infection and osteomyelitis
  • Inflammatory bowel disease, chronic diarrhea, current C. difficile infection
  • Liver cirrhosis or chronic active hepatitis
  • Treatment with medications in the past 6 months or more than a week of treatment with prednisone > 10 mg in the last 3 months
  • Anticipated kidney transplant within 9 months
  • Expected survival \< 9 months
  • Pregnancy, anticipated pregnancy, or breastfeeding
  • Incarceration
  • Participation in another intervention study
  • severe anemia defined as \< 8.0 g/dl any time during the last 2 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Patiromer

    This arm is a 2 week observation period before the start of the Patiromer treatment phase, followed by a 12 week treatment phase, and 6 week no treatment observation phase. Pre-Treatment (Wk 1-2): Observational period. Baseline sample collection of blood and stool. No medication. Treatment (Wk 3-14): Participants will take 8.4 grams of Patiromer once daily for one week, during which serum potassium and gastrointestinal symptoms will be evaluated. If tolerated and in the absence of hypokalemia, the dose will be up-titrated to 16.8 grams once daily for the remaining 11 weeks. Blood and stool will be collected. Post-Treatment (Wk 15-20): Observational period. No medication. Blood and stool will be collected.

    Drug: Patiromer

Interventions

  • Patiromer will be orally self-administered by participants.

06

What researchers measure

Primary outcomes

  1. Adverse Events of Participants Taking Patiromer in Lowering Serum Potassium Levels in End Stage Renal Disease (ESRD) Patients With Hyperkalemia Measured by Gastrointestinal Symptom Rating Scale (GSRS)

    The Gastrointestinal Symptom Rating Scale was used to measures any potential side effects due to study medication. Survey was administered at Wk 1, Wk 8, Wk 14, and Wk 20. For symptoms (abdomen pain - diarrhea) a score of 0 indicates "no discomfort", 1 = "mild discomfort", 2=moderate, 3=severe; higher score means a worse outcome For stool form, 1=Well formed, 2=Semi formed, 3= Loose, 4= Liquid;higher score means a worse outcome For number of stools per day, 1= \<1, 2=1 or 2, 3=3 or 4, 4=5 or 6,5= 7 or more; higher score means a worse outcome

    Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)

  2. Serum Potassium Level Through 12 Weeks of Treatment

    Blood was collected during Pre-Treatment week 2, Treatment Week 14, and Post-Treatment week 20

    Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)

  3. Changes in Blood Chemistry During the Study

    Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)

  4. Stool Electrolytes During the Study Phases

    Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)

Secondary outcomes

  1. Changes in Plasma Metabolites Using p-Cresol of Hyperkalemic ESRD Patients Treated With Patiromer

    Blood and stool samples collected from the ESRD patient will be collected at pre-specified time points and analyzed by untargeted and targeted metabolomics for stool and serum metabolome profiles.

    Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)

  2. Changes in Gut Microbiome of Hyperkalemic ESRD Patients Treated With Patiromer.

    Blood and stool samples collected from the ESRD patient will be collected at pre-specified time points and analyzed by metagenomics for gut microbiome profile.

    Time frame: Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-treatment)

07

Results

Posted Mar 22, 2023

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestonePatiromer
Started27
Completed26
Not completed1
Treatment
Participant flow — Treatment
MilestonePatiromer
Started26
Completed24
Not completed2
Post-Treatment
Participant flow — Post-Treatment
MilestonePatiromer
Started24
Completed24
Not completed0

Outcome measures

PrimaryAdverse Events of Participants Taking Patiromer in Lowering Serum Potassium Levels in End Stage Renal Disease (ESRD) Patients With Hyperkalemia Measured by Gastrointestinal Symptom Rating Scale (GSRS)

The Gastrointestinal Symptom Rating Scale was used to measures any potential side effects due to study medication. Survey was administered at Wk 1, Wk 8, Wk 14, and Wk 20. For symptoms (abdomen pain - diarrhea) a score of 0 indicates "no discomfort", 1 = "mild discomfort", 2=moderate, 3=severe; higher score means a worse outcome For stool form, 1=Well formed, 2=Semi formed, 3= Loose, 4= Liquid;higher score means a worse outcome For number of stools per day, 1= \<1, 2=1 or 2, 3=3 or 4, 4=5 or 6,5= 7 or more; higher score means a worse outcome

Time frame:
Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)
Reported as:
Mean · score on a scale
Adverse Events of Participants Taking Patiromer in Lowering Serum Potassium Levels in End Stage Renal Disease (ESRD) Patients With Hyperkalemia Measured by Gastrointestinal Symptom Rating Scale (GSRS)
score on a scalePre-TreatmentTreatmentPost-Treatment
Abdomen Pain.24 (.04 to .44).23 (0 to .51).16 (0 to .32)
Heartburn.08 (0 to .17).31 (.02 to .59).13 (0 to .32)
Acid Reflux.22 (.03 to .41).35 (.06 to .64).30 (.04 to .56)
Hunger Pains0 (0 to 0).19 (0 to .38).04 (0 to .13)
Nausea.44 (.14 to .75).42 (.11 to .74).14 (0 to .39)
Rumbling Stomach.34 (.14 to .54).23 (0 to .48).31 (0 to .62)
Bloated.14 (0 to .28).12 (0 to .24).14 (0 to .28)
Burping.13 (.02 to .25).08 (0 to .18).26 (0 to .57)
Flatus.53 (.18 to .88).58 (.21 to .94).60 (.18 to 1.02)
Constipation.72 (.31 to 1.12).65 (.23 to 1.08).36 (0 to .72)
Diarrhea.17 (.03 to .32).44 (.06 to .82).18 (.02 to .34)
Stool form1.43 (1.20 to 1.66)1.62 (1.39 to 1.84)1.41 (1.14 to 1.68)
Number of stool/days1.9 (1.7 to 2.2)2.1 (1.8 to 2.4)2 (1.8 to 2.2)
Statistical analysis
  • Pre-Treatment vs Treatment vs Post-Treatment · Fisher Exact · p = .05
PrimarySerum Potassium Level Through 12 Weeks of Treatment

Blood was collected during Pre-Treatment week 2, Treatment Week 14, and Post-Treatment week 20

Time frame:
Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)
Reported as:
Mean · mEq/L
Serum Potassium Level Through 12 Weeks of Treatment
mEq/LPre-TreatmentIntervention: TreatmentPost-Treatment
Serum Potassium Level Through 12 Weeks of Treatment5.7 (5.4 to 5.9)5.1 (4.9 to 5.2)5.4 (5.2 to 5.6)
Statistical analysis
  • Pre-Treatment vs Intervention: Treatment vs Post-Treatment · Mixed Models Analysis · p = .05
PrimaryChanges in Blood Chemistry During the Study
Time frame:
Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)
Reported as:
Mean · mg/dl
Changes in Blood Chemistry During the Study
mg/dlPre-TreatmentTreatmentPost-Treatment
Blood Urea Nitrogen62.2 (56.9 to 67.5)62.6 (57.3 to 67.9)59.0 (54.1 to 64.0)
Creatinine10.4 (9.7 to 11.0)10.6 (9.9 to 11.4)10.5 (9.9 to 11.1)
Sodium138.4 (137.3 to 139.5)138.5 (137.5 to 139.6)139.2 (135.7 to 142.6)
Potassium5.7 (5.4 to 5.9)5.1 (4.9 to 5.2)5.4 (5.2 to 5.6)
Chloride95.2 (94.0 to 96.5)95.1 (94.0 to 96.3)95.8 (94.6 to 97.0)
Carbon Dioxide20.3 (19.4 to 21.2)20.0 (19.1 to 20.9)20.6 (19.5 to 21.7)
Calcium8.9 (8.7 to 9.1)9.1 (8.9 to 9.4)8.7 (8.5 to 8.9)
Phosphate6.0 (5.3 to 6.7)6.0 (5.4 to 6.7)6.3 (5.7 to 7.0)
Magnesium2.6 (2.4 to 2.8)2.4 (2.3 to 2.6)2.5 (2.4 to 2.7)
Statistical analysis
  • Pre-Treatment vs Treatment vs Post-Treatment · Mixed Models Analysis · p = .05
PrimaryStool Electrolytes During the Study Phases
Time frame:
Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)
Reported as:
Mean · mcg/g
Stool Electrolytes During the Study Phases
mcg/gPre-TreatmentTreatmentPost-Treatment
Sodium343 (222 to 464)425 (288 to 562)360 (241 to 479)
Potassium4132 (3627 to 4637)5923 (4796 to 7050)4246 (3858 to 4634)
Calcium7874 (5799 to 9948)13017 (10448 to 15586)7635 (5568 to 9703)
Phosphate7719 (6630 to 8809)7067 (5780 to 8354)7670 (6341 to 8998)
Magnesium1923 (1380 to 2466)1603 (1347 to 1860)1665 (1372 to 1958)
Statistical analysis
  • Pre-Treatment vs Treatment vs Post-Treatment · Mixed Models Analysis · p = .05
SecondaryChanges in Plasma Metabolites Using p-Cresol of Hyperkalemic ESRD Patients Treated With Patiromer

Blood and stool samples collected from the ESRD patient will be collected at pre-specified time points and analyzed by untargeted and targeted metabolomics for stool and serum metabolome profiles.

Time frame:
Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-Treatment)

No measurements were reported for this outcome.

SecondaryChanges in Gut Microbiome of Hyperkalemic ESRD Patients Treated With Patiromer.

Blood and stool samples collected from the ESRD patient will be collected at pre-specified time points and analyzed by metagenomics for gut microbiome profile.

Time frame:
Wk 2 (Pre-Treatment), Wk 14 (Treatment), Wk 20 (Post-treatment)

No measurements were reported for this outcome.

Adverse events

Collected over The study period during which adverse events must be reported is defined as the period from initiation of the study procedures to the end of the treatment follow-up. In other words, AE documentation should begin when the patient signs the informed consent form. Encourage participants to contact the investigator after the conclusion of the trial if subsequent medical events occur which the participant, or the participant's physician, believes may be related to participation in the research study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patiromer0/27 (0%)11/27 (40.7%)0/27 (0%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPatiromer
HypoglycemiaMetabolism and nutrition disorders1/27
HypertensionCardiac disorders1/27
Shortness of BreathRespiratory, thoracic and mediastinal disorders1/27
FeverInfections and infestations1/27
HypoglcymiaMetabolism and nutrition disorders1/27
Shortness of BreathRespiratory, thoracic and mediastinal disorders1/27
MRSA InfectionInfections and infestations1/27
InfectionInfections and infestations1/27
Dizzy and DisorientedGeneral disorders1/27
NasueaGastrointestinal disorders1/27
Most frequent other events
Most frequent other events
EventPatiromer
hypomagnesemiaMetabolism and nutrition disorders0/27
constipationGastrointestinal disorders0/27
diarrheaGastrointestinal disorders0/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Patiromer
Mean56 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Patiromer
Female14
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patiromer
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American20
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Patiromer
United States27
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Patiromer
Mean33 ± 7
Diabetes
Diabetes(Participants)Patiromer
Count of participants11
Coronary Artery Disease
Coronary Artery Disease(Participants)Patiromer
Count of participants3
HIV
HIV(Participants)Patiromer
Count of participants5

23 further baseline measures are reported on the registry.

08

Study locations

1 site
  • DaVita K Street
    Washington, District of Columbia 20037, United States
09

References and documents

Publications

  • Amdur RL, Paul R, Barrows ED, Kincaid D, Muralidharan J, Nobakht E, Centron-Vinales P, Siddiqi M, Patel SS, Raj DS. The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis. Kidney Int. 2020 Nov;98(5):1331-1340. doi: 10.1016/j.kint.2020.06.042. Epub 2020 Aug 1. PubMed 32750456 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Dec 2020, 37 months.

Results were first posted in Mar 2023, 2 years 2 months after primary completion.

Of 41 non-industry phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's 37 months is close to that.

Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2017
First posted
Oct 31, 2017
StartActual
Nov 1, 2017
Primary completionActual
Dec 31, 2020
CompletionActual
Dec 31, 2020
Results first posted
Mar 22, 2023
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03326583
Lead sponsor
Dominic Raj
Responsible party
Dominic Raj (Director of the Division of Renal Disease and Hypertension, Professor of Medicine, George Washington University) — Sponsor-investigator
First posted
Oct 31, 2017
Start date
Nov 1, 2017
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020
Results posted
Mar 22, 2023
Last update
May 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patiromer

Start the discussion